FDA approves more affordable version of HIV-prevention shot
The FDA tentatively approved an affordable generic version of lenacapavir, a twice-yearly HIV prevention shot expected to cost $40 a year in 120 countries.
The FDA tentatively approved an affordable generic version of lenacapavir, a twice-yearly HIV prevention shot expected to cost $40 a year in 120 countries.
